Literature DB >> 15265664

Cytokine production, glutamate release and cell death in rat cultured astrocytes treated with unconjugated bilirubin and LPS.

Adelaide Fernandes1, Rui F M Silva, Ana S Falcão, Maria A Brito, Dora Brites.   

Abstract

In hyperbilirubinemic newborns, sepsis is considered a risk factor for kernicterus. Evidence shows that injury to astrocytes triggers cytokine release. We examined the effects of unconjugated bilirubin (UCB) alone, or in combination with LPS, on the release of glutamate and cytokines from astrocytes in conditions inducing less than 10% of cell death. UCB leads to an increase of extracellular glutamate and highly enhances the release of TNF-alpha and IL-1beta, while inhibiting the production of IL-6. LPS potentiates immunostimulatory properties of UCB. These results point out the role of cytokines and provide a basis for the significance of sepsis in UCB encephalopathy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15265664     DOI: 10.1016/j.jneuroim.2004.04.007

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  28 in total

Review 1.  Kernicterus and the molecular mechanisms of bilirubin-induced CNS injury in newborns.

Authors:  Jon F Watchko
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

2.  Cross-talk between neurons and astrocytes in response to bilirubin: adverse secondary impacts.

Authors:  Ana Sofia Falcão; Rui F M Silva; Ana Rita Vaz; Cátia Gomes; Adelaide Fernandes; Andreia Barateiro; Claudio Tiribelli; Dora Brites
Journal:  Neurotox Res       Date:  2014-07       Impact factor: 3.911

3.  N-methyl-aspartate receptor and neuronal nitric oxide synthase activation mediate bilirubin-induced neurotoxicity.

Authors:  Maria A Brito; Ana R Vaz; Sandra L Silva; Ana S Falcão; Adelaide Fernandes; Rui F M Silva; Dora Brites
Journal:  Mol Med       Date:  2010-06-30       Impact factor: 6.354

Review 4.  Brain Barrier Breakdown as a Cause and Consequence of Neuroinflammation in Sepsis.

Authors:  Lucineia Gainski Danielski; Amanda Della Giustina; Marwa Badawy; Tatiana Barichello; João Quevedo; Felipe Dal-Pizzol; Fabrícia Petronilho
Journal:  Mol Neurobiol       Date:  2017-01-14       Impact factor: 5.590

5.  ER stress, mitochondrial dysfunction and calpain/JNK activation are involved in oligodendrocyte precursor cell death by unconjugated bilirubin.

Authors:  Andreia Barateiro; Ana Rita Vaz; Sandra Leitão Silva; Adelaide Fernandes; Dora Brites
Journal:  Neuromolecular Med       Date:  2012-06-17       Impact factor: 3.843

6.  Bilirubin as a determinant for altered neurogenesis, neuritogenesis, and synaptogenesis.

Authors:  Adelaide Fernandes; Ana Sofia Falcão; Elsa Abranches; Evguenia Bekman; Domingos Henrique; Lorene M Lanier; Dora Brites
Journal:  Dev Neurobiol       Date:  2009-08       Impact factor: 3.964

7.  A novel brain injury mechanism after intracerebral hemorrhage: the interaction between heme products and the immune system.

Authors:  Matthew C Loftspring; Craig Hansen; Joseph F Clark
Journal:  Med Hypotheses       Date:  2009-08-28       Impact factor: 1.538

8.  Cadmium and arsenic override NF-κB developmental regulation of the intestinal UGT1A1 gene and control of hyperbilirubinemia.

Authors:  Miao Liu; Shujuan Chen; Mei-Fei Yueh; Ryoichi Fujiwara; Camille Konopnicki; Haiping Hao; Robert H Tukey
Journal:  Biochem Pharmacol       Date:  2016-04-06       Impact factor: 5.858

9.  Rat cerebellar slice cultures exposed to bilirubin evidence reactive gliosis, excitotoxicity and impaired myelinogenesis that is prevented by AMPA and TNF-α inhibitors.

Authors:  Andreia Barateiro; Helena Sofia Domingues; Adelaide Fernandes; João Bettencourt Relvas; Dora Brites
Journal:  Mol Neurobiol       Date:  2013-08-28       Impact factor: 5.590

10.  Tumor necrosis factor-alpha modulates glutamate transport in the CNS and is a critical determinant of outcome from viral encephalomyelitis.

Authors:  Jessica Carmen; Jeffrey D Rothstein; Douglas A Kerr
Journal:  Brain Res       Date:  2009-02-03       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.